CH664959A5 - METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. - Google Patents
METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. Download PDFInfo
- Publication number
- CH664959A5 CH664959A5 CH4394/86A CH439486A CH664959A5 CH 664959 A5 CH664959 A5 CH 664959A5 CH 4394/86 A CH4394/86 A CH 4394/86A CH 439486 A CH439486 A CH 439486A CH 664959 A5 CH664959 A5 CH 664959A5
- Authority
- CH
- Switzerland
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- vii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
BESCHREIBUNG Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung einer Gruppe von substituierten 2,4-Diamino-5-benzylpyrimidinen. DESCRIPTION The present invention relates to a process for the preparation of a group of substituted 2,4-diamino-5-benzylpyrimidines.
Die deutsche Patentanmeldung Nr. 2 443 682 offenbart unter anderem Verbindungen der Formel I German patent application No. 2 443 682 discloses, inter alia, compounds of the formula I.
worin wherein
R4, R5 und R6 wie oben definiert sind mit Formaldehyd 25 und einem sekundären Amin R7R8NH, umsetzt, wobei eine Verbindung der Formel V R4, R5 and R6 as defined above are reacted with formaldehyde 25 and a secondary amine R7R8NH, a compound of the formula V
H- H-
30 30th
(I) (I)
k k
R HN R HN
ch nr7r8 ch nr7r8
(V) (V)
35 35
und deren Salze, worin and their salts, in which
R1 und R: gleich oder verschieden sind und je Q 3-Alkyl, C| j-Alkoxy, Ci j-Alkenyl oder C2 rAlkenyloxy und Z Amino oder alkylsubstituiertes Amino bedeuten. R1 and R: are the same or different and each Q 3-alkyl, C | j-Alkoxy, Ci j-alkenyl or C2 rAlkenyloxy and Z are amino or alkyl-substituted amino.
Diesen Verbindungen wird antibakterielle Aktivität zugeschrieben und für 2,4-Diamino-5(4-amino-3,5-dimethoxy-benzyl)pyrimidin wurde nachträglich gefunden, dass es gute diuretische Aktivität besitzt. Antibacterial activity is attributed to these compounds and it was subsequently found that 2,4-diamino-5 (4-amino-3,5-dimethoxy-benzyl) pyrimidine had good diuretic activity.
Die deutsche Patentanmeldung Nr. 2 634 358 offenbart unter anderem Verbindungen der Formel II The German patent application No. 2 634 358 discloses inter alia compounds of the formula II
entsteht, die dann mit einer Verbindung der Formel VI KH. arises, which then with a compound of formula VI KH.
(VI), (VI),
45 45
reagiert, wobei eine Verbindug der Formel VII reacts, a compound of formula VII
O )"NH2 O) "NH2
(VII) (VII)
und deren Salze, worin and their salts, in which
R1 ein Halogenatom und R1 is a halogen atom and
Z Amino oder alkylsubstituiertes Amino bedeutet. Z means amino or alkyl-substituted amino.
Diesen Verbindungen wurde ebenfalls antibakterielle Aktivität zugeschrieben. Antibacterial activity has also been attributed to these compounds.
Eine neue Synthese der Verbindungen der Formeln I und II wurde nun gefunden. A new synthesis of the compounds of the formulas I and II has now been found.
Entsprechend betrifft die vorliegende Erfindung ein Verfahren zur Herstellung einer Verbindung der Formel III Accordingly, the present invention relates to a process for the preparation of a compound of formula III
entsteht, gefolgt von reduktiver Entfernung der Gruppe R9, wenn R9 nicht Wasserstoff bedeutet, worin 60 R4, R5 und R6 die oben beschriebene Bedeutung haben, R7 und R8 beide Cj 4-Alkyl oder R7R8NH Morpholin oder Piperidin und R9 Wasserstoff, Hydroxy, C, 4-Alkylthio oder Mercapto bedeuten, und anschliessend gegebenenfalls eine Verbindung der Formel III, worin 65 R4a Wasserstoff bedeutet, zu einer Verbindung der Formel III, worin arises, followed by reductive removal of the group R9 if R9 is not hydrogen, where 60 R4, R5 and R6 have the meaning described above, R7 and R8 are both Cj 4-alkyl or R7R8NH morpholine or piperidine and R9 is hydrogen, hydroxy, C, 4-alkylthio or mercapto, and then optionally a compound of the formula III, in which 65 R4a is hydrogen, to a compound of the formula III, in which
R4a C| 4-Alkyl bedeutet, N-alkyliert wird. R4a C | 4-alkyl means N-alkylation.
Dieses Verfahren ist besonders geeignet zur Herstellung This process is particularly suitable for production
664 959 664 959
4 4th
jener Verbindungen, worin R4 Wasserstoff bedeutet. Geeignete Reste R" und R6 sind gleich und bedeuten je Methoxy, Chlor oder C, 4-Alkyl. those compounds in which R4 is hydrogen. Suitable radicals R "and R6 are the same and each represent methoxy, chlorine or C, 4-alkyl.
Die Herstellung der Verbindung der Formel V des Verfahrens wird im allgemeinen unter den Bedingungen durch- The preparation of the compound of formula V of the process is generally carried out under the conditions
tili b die flir die inali* ran MtnniMnai von tili b die flir die inali * ran MtnniMnai from
Miocque und Vierfond (Bull. Soc. Chem. France, 1970, 1896) beschrieben sind. Die Reaktion wird zweckmässig in Gegenwart von 0,5 Mol einer Säure, wie z.B. Essigsäure, pro Mol jedes der anderen Bestandteile durchgeführt. Die Verbindung der Formel VI wird dann mit einem kleinen Über-schuss an Verbindung der Formel V in Anwesenheit einer Säure, wie p-Toluolsulfonsäure, umgesetzt. Die Reaktion wird normalerweise nicht bei erhöhter Temperatur, zweckmässig zwischen 100 C und 200 C in einem Lösungsmittel mit einem zweckmässig hohen Siedepunkt, z.B. in einem Glykol, wie Äthylenglykol, durchgeführt. Die Entschwefelung wird geeigneterweise durch Hydrogenolyse in Anwesenheit eines Ubergangsmetall-Katalysators durchgeführt, wobei Raney-Nickel besonders geeignet für dieses Verfahren ist. Diese Reaktion wird normalerweise in einem polaren Lösungsmittel, z.B. in einem Q 4-Alkanol, wie Methanol oder Äthanol, durchgeführt. Miocque and Vierfond (Bull. Soc. Chem. France, 1970, 1896) are described. The reaction is conveniently carried out in the presence of 0.5 mole of an acid, e.g. Acetic acid, performed per mole of each of the other ingredients. The compound of formula VI is then reacted with a small excess of compound of formula V in the presence of an acid such as p-toluenesulfonic acid. The reaction is normally not carried out at an elevated temperature, suitably between 100 C and 200 C in a solvent with a suitably high boiling point, e.g. in a glycol, such as ethylene glycol. The desulfurization is suitably carried out by hydrogenolysis in the presence of a transition metal catalyst, Raney nickel being particularly suitable for this process. This reaction is usually carried out in a polar solvent, e.g. in a Q 4 alkanol, such as methanol or ethanol.
Die allfällige Alkylierung der Aminogruppe NR4H wird unter Bedingungen durchgeführt, die die Aminogruppen, die am Pyrimidinring gebunden sind, nicht beeinflussen. Geeignete Bedingungen sind dem Fachmann wiederum bekannt, z.B. die Reaktion mit Ameisensäure und dem geeigneten Aldehyd. Any alkylation of the amino group NR4H is carried out under conditions which do not affect the amino groups which are bonded to the pyrimidine ring. Suitable conditions are again known to the person skilled in the art, e.g. the reaction with formic acid and the appropriate aldehyde.
Die Verbindungen der Formeln VII sind neue Zwischenprodukte und bilden als solche einen wichtigen Bestandteil der vorliegenden Erfindung. The compounds of the formulas VII are new intermediates and as such form an important part of the present invention.
Beispiel 1 example 1
Herstellung von 2,6-Diisopropyl-4-piperidinomethylanilin Preparation of 2,6-diisopropyl-4-piperidinomethylaniline
Entsprechend den Bedingungen, beschrieben von Miocque und Vierfond (Bull. Soc. Chim. France 1970, 1896), wurden 2.6-Diisopropylanilin (17,73 g, 0,10 Mol), 37%-iger wässriger Formaldehyd (8,1 ml, 0,10 Mol), Piperidin (8,52 g, 0,10 Mol). Essigsäure (3,00 g, 0,05 Mol) und Äthanol (25 ml) zusammen erhitzt, bis die Temperatur der Lösung 92 C erreichte. Dann wurde die Lösung während 24 Stunden unter Rückfluss erhitzt. Das Produkt wurde unter Vakuum destilliert (122 C bis 140 C bei 0,7 bis 0,8 mm), wobei die Titelverbindung (17,57 g, 64%) erhalten wurde. According to the conditions described by Miocque and Vierfond (Bull. Soc. Chim. France 1970, 1896), 2,6-diisopropylaniline (17.73 g, 0.10 mol), 37% aqueous formaldehyde (8.1 ml, 0.10 mol), piperidine (8.52 g, 0.10 mol). Acetic acid (3.00 g, 0.05 mol) and ethanol (25 ml) heated together until the temperature of the solution reached 92 ° C. Then the solution was heated under reflux for 24 hours. The product was distilled under vacuum (122 C to 140 C at 0.7 to 0.8 mm) to give the title compound (17.57 g, 64%).
"H NMR (CDClj): 5 1,25 (d, 12, CH3), 1,50 (m, 6, (CH-h). 2.35 (m, 4, N(OL)-,), 2,95 (m, 2, CH), 3,35 (s, 2, Ar-CH:), 3,70 (breit, s, 2, NH2), 7,0 (s, 2, Ar-H). "H NMR (CDClj): 5 1.25 (d, 12, CH3), 1.50 (m, 6, (CH-h). 2.35 (m, 4, N (OL) -,), 2.95 (m, 2, CH), 3.35 (s, 2, Ar-CH :), 3.70 (broad, s, 2, NH2), 7.0 (s, 2, Ar-H).
Beispiel 2 Example 2
Herstellung von 2,6-Diäthyl-4-pipendinomethylanilin Preparation of 2,6-diethyl-4-pipendinomethylaniline
Eine Lösung von 2,6-Diäthylanilin (29,85 g, 0,20 Mol), 37%igem wässrigem Formaldehyd (16,2 ml, 0,20 Mol), Piperidin (17,03 g, 0,20 Mol), Essigsäure (6,00 g, 0,10 Mol), und Äthanol (25 ml) wurde unter ähnlichen Bedingungen wie in Beispiel 1 zur Reaktion gebracht. A solution of 2,6-diethylaniline (29.85 g, 0.20 mol), 37% aqueous formaldehyde (16.2 ml, 0.20 mol), piperidine (17.03 g, 0.20 mol), Acetic acid (6.00 g, 0.10 mol) and ethanol (25 ml) were reacted under conditions similar to Example 1.
Die Titelverbindung (28,49 g, 57,8%) wurde durch Vakuumdestillation (115 C bis 125 C bei 0,05 mm) isoliert. The title compound (28.49 g, 57.8%) was isolated by vacuum distillation (115 C to 125 C at 0.05 mm).
'H NMR (CDCU): S 1,25 (t, 6, CH,), 1,50 (m, 6, (CHo)3), 2.35 (m. 4. N(CH-.)->j, 2,55 (q, 4, CH,M~e), 3,45 (s, 2, 'H NMR (CDCU): S 1.25 (t, 6, CH,), 1.50 (m, 6, (CHo) 3), 2.35 (m. 4. N (CH -.) -> j, 2.55 (q, 4, CH, M ~ e), 3.45 (s, 2,
ArCH:). 3.55 (breit s, 2, NH2), 6,90 (s, 2, ArH). ARCH :). 3.55 (broad s, 2, NH2), 6.90 (s, 2, ArH).
Beispiel 3 Example 3
Herstellung von 2,6-Diisopropyl-4-( N,N-Dimetliyiaminome-thyl umilili Preparation of 2,6-diisopropyl-4- (N, N-dimethylamine amyl umilili
Eine Lösung von 2,6-Diisopropylanilin (35,45 g, 0.20 Mol), 37%-igem wässrigem Formaldehyd (16,2 ml, 0.20 Mol). N.N-Dimethylamin (9,02 g, 0,20 Mol), Essigsäure (6,00 g, 0,10 Mol) und Äthanol (25 ml) wurde unter ähnlichen Bedingungen wie im Beispiel 1 zur Reaktion gebracht. A solution of 2,6-diisopropylaniline (35.45 g, 0.20 mol), 37% aqueous formaldehyde (16.2 ml, 0.20 mol). N.N-dimethylamine (9.02 g, 0.20 mol), acetic acid (6.00 g, 0.10 mol) and ethanol (25 ml) were reacted under conditions similar to Example 1.
Die Titelverbindung (12,05 g, 26%) wurde durch Vakuumdestillation (112 C bis 120 C, 0,2 mm) isoliert. The title compound (12.05 g, 26%) was isolated by vacuum distillation (112 C to 120 C, 0.2 mm).
'H NMR (CDCL): 5 1,25 (d, 12, CH-.), 2,20 (s, 6, NMe,), 'H NMR (CDCL): 5 1.25 (d, 12, CH-.), 2.20 (s, 6, NMe,),
u?5 (m. : oi). ]j] (i : Areni), UM 11 mia " u? 5 (m.: oi). ] j] (i: Areni), UM 11 mia "
7,0 (s. 2. ArH). 7.0 (see 2nd ArH).
Beispiel 4 Example 4
Herstellung von 2,6-Diisopropyl-4-morpholmomethylanilm Preparation of 2,6-diisopropyl-4-morpholmomethylanilm
Eine Lösung von 2,6-Diisopropylanilin (35,45 g, 0,20 Mol), 37%-igem wässrigem Formaldehyd (16,2 ml, 0,20 Mol), Morpholin ( 17,42 g, 0,20 Mol), Essigsäure (6,00 g, 0,10 Mol), und Äthanol (25 ml) wurden unter ähnlichen Bedingungen wie in Beispiel 1 zur Reaktion gebracht. Nach dem Konzentrieren am Rotationsverdampfer wurde der Rückstand in Diäthyläther gelöst und mit wässrigem Natrium-bicarbonat und Wasser gewaschen. Nach der Trocknung der Ätherlösung wurde eine Lösung von Chlorwasserstoff (0,20 Mol) in Äthanol zugegeben. Eine Filtration und Trocknung ergab das Hydrochloridsalz der Titelverbindung (47,58 g, 76,0%). Das Salz (20,0 g, 0,6 Mol), wurde in Aceton gelöst und mit festem Kaliumbicarbonat behandelt. Nach Filtration und Abdampfen des Lösungsmittels wurde die Titelverbindung erhalten (16,27 g, 92,2%). A solution of 2,6-diisopropylaniline (35.45 g, 0.20 mol), 37% aqueous formaldehyde (16.2 ml, 0.20 mol), morpholine (17.42 g, 0.20 mol) , Acetic acid (6.00 g, 0.10 mol), and ethanol (25 ml) were reacted under conditions similar to Example 1. After concentrating on a rotary evaporator, the residue was dissolved in diethyl ether and washed with aqueous sodium bicarbonate and water. After the ether solution had dried, a solution of hydrogen chloride (0.20 mol) in ethanol was added. Filtration and drying gave the hydrochloride salt of the title compound (47.58 g, 76.0%). The salt (20.0 g, 0.6 mol) was dissolved in acetone and treated with solid potassium bicarbonate. After filtration and evaporation of the solvent, the title compound was obtained (16.27 g, 92.2%).
C|7H-.8N->: berechnet: C 73,87; H 10,21; N 10,13 gefunden: C 74,04; H 10,31; N 10,17. C | 7H-.8N->: Calculated: C 73.87; H 10.21; N 10.13 Found: C 74.04; H 10.31; N 10.17.
Beispiel 5 Example 5
Herstellung von 2,4-Diamino-5-( 4-amino-3,5-diisopropytben-zyl ) -6-methylthiopyrimidin Preparation of 2,4-diamino-5- (4-amino-3,5-diisopropytbenzyl) -6-methylthiopyrimidine
Zu 2,4-Diamino-6-methylthiopyrimidin (1,56 g, 10.0 mMol) in Äthylenglykol (50 ml) wurde bei 114 C eine Lösung von V (R4=H, R5 = R5=CHMe:, NR7R8 = Mor-pholino, 3,32 g, 12,0 mMol) in Äthylenglykol (25 ml) und p-Toluolsulfonsäuremonohydrat (0,19 g, 1,0 mMol) hinzugegeben. Die Temperatur wurde während 3'/4 Stunden zwischen 125 C und 140 C gehalten, dann wurde das Lösungsmittel unter Vakuum abdestilliert und 3N Salzsäure (20 ml) zum Rückstand gegeben. Das rohe Hydrochloridsalz der Titelverbindung (3,44 g, 90,0%) wurde in Methanol gelöst, mit Aktivkohle behandelt, filtriert und eingedampft, bis die Kristallisation einsetzte. Die Aufschlämmung wurde mit Iso-propanol verdünnt, filtriert und getrocknet, wobei das gereinigte Hydrochloridsalz der Titelverbindung erhalten wurde (2,58 g, 68%). A solution of V (R4 = H, R5 = R5 = CHMe :, NR7R8 = Morpholino) was added to 2,4-diamino-6-methylthiopyrimidine (1.56 g, 10.0 mmol) in ethylene glycol (50 ml) at 114 ° C , 3.32 g, 12.0 mmol) in ethylene glycol (25 ml) and p-toluenesulfonic acid monohydrate (0.19 g, 1.0 mmol) added. The temperature was maintained between 125 ° C and 140 ° C for 3/4 hours, then the solvent was distilled off under vacuum and 3N hydrochloric acid (20 ml) was added to the residue. The crude hydrochloride salt of the title compound (3.44 g, 90.0%) was dissolved in methanol, treated with activated carbon, filtered and evaporated until crystallization started. The slurry was diluted with isopropanol, filtered and dried to give the purified hydrochloride salt of the title compound (2.58 g, 68%).
Die Titelverbindung wurde erhalten durch Zugabe von konzentriertem Ammoniumhydroxyd (6 ml) zu einer wässri-gen Lösung des Hydrochloridsalzes (1,67 g, 4,37 mMol). Eine Filtration und Trocknung ergab die Titelverbindung (1,38 g, 91,4%). The title compound was obtained by adding concentrated ammonium hydroxide (6 ml) to an aqueous solution of the hydrochloride salt (1.67 g, 4.37 mmol). Filtration and drying gave the title compound (1.38 g, 91.4%).
'H NMR (CDC1.0: 8 1,30 (d, 12, CH3), 2,60 (s, 3, SCH3), 3.0 (m, 2, CH), 3,6 (breit s, 2, ArNH-.), 3,35 (s, 2, ArCH-,), 4,7 (breit s, 4, NH2), 7,0 (s, 2, ArH). 'H NMR (CDC1.0: 8 1.30 (d, 12, CH3), 2.60 (s, 3, SCH3), 3.0 (m, 2, CH), 3.6 (broad s, 2, ArNH -.), 3.35 (s, 2, ArCH-), 4.7 (broad s, 4, NH2), 7.0 (s, 2, ArH).
In ähnlicher Weise wurde VI (R9 = SCH3, 1,56 g, 10.0 mMol) mit V (R4 = H, R5 = R6=CHMe2, NR7R8= Pi-peridino, 3,29 g, 12,0 mMol) umgesetzt, wobei die Titelverbindung erhalten wurde (1,41 g, 41%). Similarly, VI (R9 = SCH3, 1.56 g, 10.0 mmol) was reacted with V (R4 = H, R5 = R6 = CHMe2, NR7R8 = Pi-peridino, 3.29 g, 12.0 mmol), whereby the title compound was obtained (1.41 g, 41%).
Ebenso wurde unter ähnlichen Bedingungen VI (R9 = SCH3, 1,56 g, 10,0 mMol) mit V(R4=H, R5 = R6 = CHMe2, R7 = RS = CH3, 2,81 g, 12,0 mMol) umgesetzt, wobei die Titelverbindung (0,97 g, 28,4%) entstand. Likewise, under similar conditions VI (R9 = SCH3, 1.56 g, 10.0 mmol) with V (R4 = H, R5 = R6 = CHMe2, R7 = RS = CH3, 2.81 g, 12.0 mmol) reacted, the title compound (0.97 g, 28.4%) being formed.
Beispiel 6 Example 6
Herstellung von 2.4-Diamim>-5-( 4-ctmino-3,5-Diisopropylhen-zyl jpyriniidin Preparation of 2,4-Diamim> -5- (4-ctmino-3,5-Diisopropylhen-zyl jpyriniidin
5 5
10 10th
15 15
20 20th
25 25th
30 30th
35 35
40 40
45 45
50 50
55 55
60 60
65 65
5 5
664 959 664 959
Eine Lösung von VII (R4=H, R5=R6 = CHMe2, R9 = SCH3, 0,50 g, 1,45 mMol) in Methylcellosolve (10 ml) und Wasser (0,5 ml) wurde während 6 Stunden mit T-l Ra-ney-Nickel (3 g) unter Rückfluss erhitzt. Die Lösung wurde filtriert, und eingedampft, und der Rückstand wurde mit heissem Hexan zerrieben, wobei die Titelverbindung entstand (0,36 g, 84%), Schmelzpunkt 177 C bis 180 C. A solution of VII (R4 = H, R5 = R6 = CHMe2, R9 = SCH3, 0.50 g, 1.45 mmol) in methyl cellosolve (10 ml) and water (0.5 ml) was treated with Tl Ra for 6 hours -ney nickel (3 g) heated under reflux. The solution was filtered and evaporated and the residue was triturated with hot hexane to give the title compound (0.36 g, 84%), melting point 177 C to 180 C.
Beispiel 7 Example 7
Herstellung von 2,4-Diamino-5-(4-amino-3,5-diisopropylben-:yl)-6-hydroxypyrimidin Preparation of 2,4-diamino-5- (4-amino-3,5-diisopropylben-: yl) -6-hydroxypyrimidine
Eine Lösung von VI • H-.0 (R9=OH, 1,44 g, A solution of VI • H-.0 (R9 = OH, 1.44 g,
10,0 mMol), V (R4 = H, R5 = R6 = CHMe2, NR7R8 = Mor-pholino, 3,32 g, 12,0 mMol) und p-Toluolsulfonsäuremono-hydrat (0,19 g, 1,0 mMol) in Äthylenglykol (75 ml) wurde während 4'/2 Stunden bei 133 C bis 138 C gehalten. Das Lösungsmittel wurde unter Vakuum abdestilliert und 3N Salzsäure {20 ml) wurde zum Rückstand gegeben. Das resultierende Hydrochloridsalz wurde isoliert, in Wasser gelöst und durch Zugabe von konzentriertem Ammoniumhydroxid neutralisiert, wobei die Titelverbindung entstand (2,36 g, 74,9%). Die Titelverbindung wurde durch Umkristallisie-rung aus Äthanol gereinigt (1,44 g, 45,7%). 10.0 mmol), V (R4 = H, R5 = R6 = CHMe2, NR7R8 = Morpholino, 3.32 g, 12.0 mmol) and p-toluenesulfonic acid monohydrate (0.19 g, 1.0 mmol ) in ethylene glycol (75 ml) was kept at 133 C to 138 C for 4 1/2 hours. The solvent was distilled off under vacuum and 3N hydrochloric acid (20 ml) was added to the residue. The resulting hydrochloride salt was isolated, dissolved in water and neutralized by adding concentrated ammonium hydroxide to give the title compound (2.36 g, 74.9%). The title compound was purified by recrystallization from ethanol (1.44 g, 45.7%).
'H NMR (DMSO-d6): 8 1,05 (d, 6, CH,), 2,90 (m, 2, CH), 3,30 (s, 2. ArCH->), 4,15 (breit s, 2, ArNH,), 5,45 (breit s, 2, NH-0, 4,15 (breit s, 2, NH->), 6,80 (s, 2, ArH), 9,90 (s, 1, OH). 'H NMR (DMSO-d6): 8 1.05 (d, 6, CH,), 2.90 (m, 2, CH), 3.30 (s, 2nd ArCH->), 4.15 ( broad s, 2, ArNH,), 5.45 (broad s, 2, NH-0, 4.15 (broad s, 2, NH->), 6.80 (s, 2, ArH), 9.90 (s, 1, OH).
Die Titelberbindung kann durch nachfolgende Reaktion mit Methansulfonsäurechlorid zu VII (R9=0S02Me), gefolgt von katalytischer Hydrierung mit Palladium zur Verbindung VII (R9=H) überführt werden, wie z.B. im britischen Patent Nr. I 542 804. The title linkage can be converted to VII (R9 = 0S02Me) by subsequent reaction with methanesulfonic acid chloride, followed by catalytic hydrogenation with palladium to give compound VII (R9 = H), e.g. in British Patent No. I 542 804.
5 Beispiel 8 5 Example 8
Herstellung von 2,4-Diamino-5-(4-amino-3,5-diisopropylben-zyDpyrimidin Preparation of 2,4-diamino-5- (4-amino-3,5-diisopropylbenzyDpyrimidine
Eine Lösung von VI (R9 = H, 1,10 g, 10,0 mMol), V (R4=H, R5 = R6=CHMe2, NR7R8 = Morpholino, 3,32 g, 10 12,0 mMol) und p-Toluolsulfonsäuremonohydrat (0,19 g, 1,0 mMol) in Äthylenglykol (50 ml) wurde während 57z Stunden auf 150 C bis 160 X erhitzt. Das Lösungsmittel wurde unter Vakuum abdestilliert und 3N Salzsäure (20 ml) wurde zum Rückstand gegeben. Die resultierende Lösung wurde mit Methylenchlorid gewaschen und zu einem Öl eingedampft, das beim Stehenlassen kristallisierte. Die Kristalle wurden mit Isopropanol zerrieben, filtriert und getrocknet, wobei das Hydrochloridsalz der Titelverbindung (1,51 g, 45%) erhalten wurde, das aus Äthanol umkristallisiert wur-20 de (1,04 g, 68,9%). A solution of VI (R9 = H, 1.10 g, 10.0 mmol), V (R4 = H, R5 = R6 = CHMe2, NR7R8 = Morpholino, 3.32 g, 10 12.0 mmol) and p- Toluenesulfonic acid monohydrate (0.19 g, 1.0 mmol) in ethylene glycol (50 ml) was heated at 150 ° C. to 160 ° C. for 57 hours. The solvent was distilled off under vacuum and 3N hydrochloric acid (20 ml) was added to the residue. The resulting solution was washed with methylene chloride and evaporated to an oil which crystallized on standing. The crystals were triturated with isopropanol, filtered and dried to give the hydrochloride salt of the title compound (1.51 g, 45%), which was recrystallized from ethanol-20 de (1.04 g, 68.9%).
Die Zugabe von 3N Natriumhydroxid zur wässrigen Lösung des Hydrochloridsalzes (0,74 g, 2,20 mMol) ergab die Titelverbindung (0,50 g, 76%). The addition of 3N sodium hydroxide to the aqueous solution of the hydrochloride salt (0.74 g, 2.20 mmol) gave the title compound (0.50 g, 76%).
'H NMR (DMSO-d6): 5 1,15 (d, 12, CH3), 2,95 (m, 2, 25 CH), 3,50 (s, 2, ArCHO, 4,50 (breit s, 2, ArNH2), 6,15 (breit s, 2, NH2), 6,55 (breit s, 2, NH2), 6,80 (s, 2, ArH), 7,40 (s, 1, Pyrimidin 5-H). Schmelzpunkt 179 'C bis 182 C. 'H NMR (DMSO-d6): 5 1.15 (d, 12, CH3), 2.95 (m, 2, 25 CH), 3.50 (s, 2, ArCHO, 4.50 (broad s, 2, ArNH2), 6.15 (broad s, 2, NH2), 6.55 (broad s, 2, NH2), 6.80 (s, 2, ArH), 7.40 (s, 1, pyrimidine 5 -H). Melting point 179 'C to 182 C.
C C.
Claims (5)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31964381A | 1981-11-09 | 1981-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH664959A5 true CH664959A5 (en) | 1988-04-15 |
Family
ID=23243118
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH4395/86A CH664960A5 (en) | 1981-11-09 | 1982-11-08 | METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
CH6481/82A CH658246A5 (en) | 1981-11-09 | 1982-11-08 | METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
CH4396/86A CH664961A5 (en) | 1981-11-09 | 1982-11-08 | INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
CH4394/86A CH664959A5 (en) | 1981-11-09 | 1982-11-08 | METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH4395/86A CH664960A5 (en) | 1981-11-09 | 1982-11-08 | METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
CH6481/82A CH658246A5 (en) | 1981-11-09 | 1982-11-08 | METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
CH4396/86A CH664961A5 (en) | 1981-11-09 | 1982-11-08 | INTERMEDIATE PRODUCTS FOR THE SYNTHESIS OF SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. |
Country Status (5)
Country | Link |
---|---|
JP (4) | JPS5888368A (en) |
CH (4) | CH664960A5 (en) |
DE (1) | DE3241134C2 (en) |
FR (1) | FR2516081B1 (en) |
GB (3) | GB2109375B (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE323746C (en) | 1919-10-30 | 1920-08-04 | Huebner Johannes | Fire protection apparatus for cinematographic projection apparatus |
GB1401612A (en) * | 1971-04-16 | 1975-07-16 | Wellcome Found | 2,4-diamino-5-benzylpyrimidines and preparations thereof |
AT323745B (en) * | 1971-04-16 | 1975-07-25 | Wellcome Found | METHOD FOR PRODUCING NEW 2,4-DIAMINO-5-BENZYLPYRIMIDINES OR THEIR SALT |
CH592066A5 (en) * | 1973-02-26 | 1977-10-14 | Hoffmann La Roche | |
US3923807A (en) * | 1973-09-10 | 1975-12-02 | Takeda Chemical Industries Ltd | 6-Aminouracil derivatives |
CH591456A5 (en) * | 1973-09-12 | 1977-09-15 | Hoffmann La Roche | |
US4008236A (en) * | 1975-07-31 | 1977-02-15 | Abbott Laboratories | 2,4-Diamino-5-benzylpyrimidines |
JPS5353385A (en) * | 1976-10-26 | 1978-05-15 | Seiko Epson Corp | Clocking device |
GR71725B (en) * | 1977-11-10 | 1983-06-22 | Hoffmann La Roche | |
CH639273A5 (en) * | 1978-09-12 | 1983-11-15 | Hoffmann La Roche | DIURETIC MEANS. |
-
1982
- 1982-11-08 CH CH4395/86A patent/CH664960A5/en not_active IP Right Cessation
- 1982-11-08 CH CH6481/82A patent/CH658246A5/en not_active IP Right Cessation
- 1982-11-08 CH CH4396/86A patent/CH664961A5/en not_active IP Right Cessation
- 1982-11-08 JP JP57195848A patent/JPS5888368A/en active Granted
- 1982-11-08 CH CH4394/86A patent/CH664959A5/en not_active IP Right Cessation
- 1982-11-08 DE DE3241134A patent/DE3241134C2/en not_active Expired - Fee Related
- 1982-11-08 FR FR8218670A patent/FR2516081B1/en not_active Expired
- 1982-11-09 GB GB08231983A patent/GB2109375B/en not_active Expired
-
1985
- 1985-06-24 GB GB08515932A patent/GB2161158B/en not_active Expired
- 1985-06-24 GB GB08515931A patent/GB2161805B/en not_active Expired
-
1993
- 1993-01-28 JP JP5012770A patent/JPH07606B2/en not_active Expired - Lifetime
-
1994
- 1994-06-15 JP JP6133295A patent/JP2657150B2/en not_active Expired - Lifetime
-
1997
- 1997-02-20 JP JP9036735A patent/JPH09227530A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB8515932D0 (en) | 1985-07-24 |
DE3241134C2 (en) | 1996-04-11 |
JPH09227530A (en) | 1997-09-02 |
CH664961A5 (en) | 1988-04-15 |
CH664960A5 (en) | 1988-04-15 |
JPS5888368A (en) | 1983-05-26 |
CH658246A5 (en) | 1986-10-31 |
JP2657150B2 (en) | 1997-09-24 |
GB2109375A (en) | 1983-06-02 |
GB2161158A (en) | 1986-01-08 |
JPH069576A (en) | 1994-01-18 |
JPH08188574A (en) | 1996-07-23 |
DE3241134A1 (en) | 1983-05-19 |
GB8515931D0 (en) | 1985-07-24 |
GB2161805A (en) | 1986-01-22 |
JPH0549665B2 (en) | 1993-07-26 |
FR2516081B1 (en) | 1987-05-29 |
FR2516081A1 (en) | 1983-05-13 |
GB2161805B (en) | 1986-07-30 |
GB2161158B (en) | 1986-07-30 |
GB2109375B (en) | 1986-08-06 |
JPH07606B2 (en) | 1995-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1112079B (en) | Process for the preparation of 3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes | |
DD216934A5 (en) | PROCESS FOR THE PREPARATION OF NEW DERIVATIVES OF XANTHINES | |
DE2340873A1 (en) | MORPHOLINE DERIVATIVES | |
DE3043159C2 (en) | Cyclic acetals of glutamic acid-γ-semialdehyde, process for their preparation and their use | |
DE2534962C3 (en) | cis-3,4-ureylenethiophane-l, l-dioxide and process for its preparation | |
CH664959A5 (en) | METHOD FOR PRODUCING SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES. | |
DE2040510A1 (en) | 2-amino-4,5,7,8-tetrahydro-6h-thiazolo-or oxazolo(5,4-d) - azepines - as hypotensive, antiphlogistic, sedative and bechic agents | |
DE1593837A1 (en) | Process for the preparation of new aminoketones | |
DE1543809A1 (en) | Process for the preparation of amino compounds | |
DE1150991B (en) | Process for the preparation of 7-sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes | |
DE1815618B2 (en) | HYDROXY-PHENALKYLAMINOKETONE | |
DE1670093C3 (en) | Process for the preparation of hexahydropyrimidine derivatives | |
DE1670583A1 (en) | New piperidine derivatives | |
DE586879C (en) | Process for the preparation of pyridine compounds containing basic groups | |
US4568744A (en) | Benzylpyrimidine synthesis and intermediates | |
DE1620285A1 (en) | Process for the preparation of thiazole compounds | |
DE972617C (en) | Process for the preparation of 5-amino-1, 3-dioxanes | |
DE1593836A1 (en) | Process for the preparation of new aminoketones | |
DE1125938B (en) | Process for the preparation of 7-sulfamyl-3, 4-dihydro-1, 2, 4-benzothiadiazine-1, 1-dioxydes | |
AT220143B (en) | Process for the preparation of new tertiary amines and their acid addition and quaternary ammonium salts | |
CH390935A (en) | Process for the preparation of benzene disulfonamides | |
DE1143201B (en) | Process for the preparation of 2-phenyl-3, 6-dimethylmorpholine | |
DE1134997B (en) | Process for the preparation of 1-isopropyl-pyrazolo- [3, 4-d] -pyrimidines | |
DE828695B (en) | Process for the preparation of new Piperazmdenvaten | |
DE2328972A1 (en) | N-alkyl-benzoyl aminobenzylamines - by direct alkylation antitussives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUE | Assignment |
Owner name: MALLINCKRODT VETERINARY, INC. |
|
PL | Patent ceased |